Browse > Article
http://dx.doi.org/10.7586/jkbns.2018.20.2.55

Current Pharmacogenetic Approach for Oxaliplatin-induced Peripheral Neuropathy among Patients with Colorectal Cancer: A Systematic Review  

Ahn, Soojung (The Graduate School of Yonsei University)
Choi, Soyoung (The Graduate School of Yonsei University)
Jung, Hye Jeong (Severance Hospital)
Chu, Sang Hui (College of Nursing.Mo-Im Kim Nursing Research Institute, Yonsei University)
Publication Information
Journal of Korean Biological Nursing Science / v.20, no.2, 2018 , pp. 55-66 More about this Journal
Abstract
Purpose: Peripheral neuropathy is common among colorectal cancer (CRC) patients who undergo oxaliplatin-based (OXL) chemotherapy. A pharmacogenetic approach can be used to identify patients at high-risk of developing severe neuropathy. This type of approach can also help clinicians determine the best treatment option and prevent severe neurotoxicity. The purpose of this study is to investigate the evidence of pharmacogenetic markers for OXL-induced peripheral neuropathy (OXIPN) in patients with CRC. Methods: A systematic literature search was conducted using the following databases up to December 2017: Pubmed, EMBASE, and CINAHL. We reviewed the genetic risk factors for OXIPN in observational studies and randomized controlled clinical trials (RCTs). All processes were performed independently by two reviewers. Results: Sixteen studies published in English between 2006 and 2017 were included in this review. A genome-wide association approach was used in one study and various candidate genes were tested, based on their functions (e.g., DNA damage or repair, ion channels, anti-oxidants, and nerve growth etc.). The genes associated with incidence or severity of OXIPN were ABCG2, GSTP1, XRCC1, TAC1, and ERCC1. Conclusion: This study highlighted the need and the importance of conducting pharmacogenetic studies to generate evidence of personalized OXIPN symptoms management. Additional studies are warranted to accelerate the tailored interventions used for OXIPN in patients with CRC (NRF-2014R1A1A3054386).
Keywords
Oxaliplatin; Peripheral neuropathy; Pharmacogenetics; Colorectal cancer;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Terrazzino S, Argyriou AA, Cargnin S, Antonacopoulou AG, Briani C, Bruna J, et al. Genetic determinants of chronic oxaliplatin-induced peripheral neurotoxicity: A genome-wide study replication and meta-analysis. Journal of the Peripheral Nervous System. 2015;20(1):15-23. http://doi.org/10.1111/jns.12110   DOI
2 Argyriou A. Updates on oxaliplatin-induced peripheral neurotoxicity (OXAIPN). Toxics. 2015;3(2):187-197. http://doi.org/10.3390/toxics3020187   DOI
3 Argyriou A, Kyritsis A, Makatsoris T, Kalofonos H. Chemotherapy-induced peripheral neuropathy in adults: A comprehensive update of the literature. Cancer Management and Research. 2014;6:135-147. http://doi.org/10.2147/CMAR.S44261
4 Han FF, Guo CL, Yu D, Zhu J, Gong LL, Li GR, et al. Associations between UGT1A1* 6 or UGT1A1*6/*28 polymorphisms and irinotecan-induced neutropenia in Asian cancer patients. Cancer Chemotherapy and Pharmacology. 2014;73(4):779-788. http://doi.org/10.1007/s00280-014-2405-0   DOI
5 Chang MH, Kim KH, Jun HJ, Kim HS, Yi SY, Uhm JE, et al. Irinotecan and oxaliplatin combination as the first-line treatment for patients with advanced nonsmall cell lung cancer. Cancer Chemotherapy and Pharmacology. 2009;64(5):917-924. http://doi.org/10.1007/s00280-009-0943-7   DOI
6 Di Francia R, Siesto RS, Valente D, Del Buono A, Pugliese S, Cecere S, et al. Current strategies to minimize toxicity of oxaliplatin: selection of pharmacogenomic panel tests. Anti-Cancer Drugs. 2013;24(10):1069-1078. http://doi.org/10.1097/CAD.0000000000000002   DOI
7 Alberti P, Cavaletti G. Management of side effects in the personalized medicine era: Chemotherapy-induced peripheral neuropathy. Methods in Molecular Biololgy Pharmacogenomics in Drug Discovery and Development. 2014;1175:301-322. http://doi.org/10.1007/978-1-4939-0956-8_12
8 Lecomte T, Landi B, Beaune P, Laurent-Puig P, Loriot MA. Glutathione S-transferase P1 polymorphism (Ile105Val) predicts cumulative neuropathy in patients receiving oxaliplatin-based chemotherapy. Clincal Cancer Research. 2006;12(10):3050-3056. http://doi.org/10.1158/1078-0432.ccr-05-2076   DOI
9 Cortejoso L, Garcia MI, Garcia-Alfonso P, Gonzalez-Haba E, Escolar F, Sanjurjo M, et al. Differential toxicity biomarkers for irinotecan-and oxaliplatin-containing chemotherapy in colorectal cancer. Cancer Chemotherapy and Pharmacology. 2013;71(6):1463-1472. http://doi.org/10.1007/s00280-013-2145-6   DOI
10 Won HH, Lee J, Park JO, Park YS, Lim HY, Kang WK, et al. Polymorphic markers associated with severe oxaliplatin-induced, chronic peripheral neuropathy in colon cancer patients. Cancer. 2012;118(11):2828-2836. http://doi.org/10.1002/cncr.26614   DOI
11 Hong J, Han SW, Ham HS, Kim TY, Choi IS, Kim BS, et al. Phase II study of biweekly S-1 and oxaliplatin combination chemotherapy in metastatic colorectal cancer and pharmacogenetic analysis. Cancer Chemotherapy and Pharmacology. 2011;67(6):1323-1331. http://doi.org/10.1007/s00280-010-1425-7   DOI
12 Lee KH, Chang HJ, Han SW, Oh DY, Im SA, Bang YJ, et al. Pharmacogenetic analysis of adjuvant FOLFOX for Korean patients with colon cancer. Cancer chemotherapy and pharmacology. 2013;71(4):843-851. http://doi.org/10.1007/s00280-013-2075-3   DOI
13 Taron M, Ichinose Y, Rosell R, Mok T, Massuti B, Zamora L, et al. Activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor are associated with improved survival in gefitinib-treated chemorefractory lung adenocarcinomas. Clinical Cancer Research. 2005;11(16):5878-5885. http://doi.org/10.1158/1078-0432.CCR-04-2618   DOI
14 Boige V, Mendiboure J, Pignon JP, Loriot MA, Castaing M, Barrois M, et al. Pharmacogenetic assessment of toxicity and outcome in patients with metastatic colorectal cancer treated with LV5FU2, FOLFOX, and FOLFIRI: FFCD 2000-05. Journal of Clinical Oncology. 2010;28(15):2556-2564. http://doi.org/10.1200/jco.2009.25.2106   DOI
15 Argyriou AA, Antonacopoulou AG, Scopa CD, Kottorou A, Kominea A, Peroukides S, et al. Liability of the voltage-gated sodium channel gene SCN2A R19K polymorphism to oxaliplatin-induced peripheral neuropathy. Oncology. 2009;77(3-4):254-256. http://doi.org/ 10.1159/000236049   DOI
16 Kanai M, Yoshioka A, Tanaka S, Nagayama S, Matsumoto S, Nishimura T, et al. Associations between glutathione S-transferase Ile105Val and glyoxylate aminotransferase Pro11Leu and Ile340Met polymorphisms and early-onset oxaliplatin-induced neuropathy. Cancer epidemiology. 2010;34(2):189-193. http://doi.org/10.1016/j.canep.2010.02.008   DOI
17 Stubblefield MD, Burstein HJ, Burton AW, Custodio CM, Deng GE, Ho M, et al. NCCN task force report: Management of neuropathy in cancer. Journal of National Comprehensive Cancer Network. 2009;7(Suppl 5):S1-S26.
18 McLeod HL, Sargent DJ, Marsh S, Green EM, King CR, Fuchs CS, et al. Pharmacogenetic predictors of adverse events and response to chemotherapy in metastatic colorectal cancer: Results from North American Gastrointestinal Intergroup Trial N9741. Journal of Clinical Oncology. 2010;28(20):3227-3233. http://doi.org/10.1200/jco.2009.21.7943   DOI
19 Antonacopoulou AG, Argyriou AA, Scopa CD, Kottorou A, Kominea A, Peroukides S, et al. Integrin beta-3 L33P: A new insight into the pathogenesis of chronic oxaliplatin-induced peripheral neuropathy? European Journal of Neurology. 2010;17(7):963-968. http://doi.org/10.1111/j.1468-1331.2010.02966.x   DOI
20 Grisold W, Cavaletti G, Windebank AJ. Peripheral neuropathies from chemotherapeutics and targeted agents: Diagnosis, treatment, and prevention. Neuro-Oncology. 2012;14(Suppl 4):iv45-54. http://doi.org/10.1093/neuonc/nos203
21 Calvo E, Baselga J. Ethnic differences in response to epidermal growth factor receptor tyrosine kinase inhibitors. Journal of Clinical Oncology. 2006;24(14): 2158-2163. http://doi.org/10.1200/jco.2006.06.5961   DOI
22 Braun MS, Richman SD, Thompson L, Daly CL, Meade AM, Adlard JW, et al. Association of molecular markers with toxicity outcomes in a randomized trial of chemotherapy for advanced colorectal cancer: The FOCUS trial. Journal of Clinical Oncology. 2009;27(33):5519-5528. http://doi.org/10.1200/jco.2008.21.6283   DOI
23 Pare L, Marcuello E, Altes A, del Rio E, Sedano L, Salazar J, et al. Pharmacogenetic prediction of clinical outcome in advanced colorectal cancer patients receiving oxaliplatin/5-fluorouracil as first-line chemotherapy. British Journal of Cancer. 2008;99(7):1050-1055. http://doi.org/10.1038/sj.bjc.6604671   DOI
24 Gamelin L, Capitain O, Morel A, Dumont A, Traore S, Anne le B, et al. Predictive factors of oxaliplatin neurotoxicity: The involvement of the oxalate outcome pathway. Clinical Cancer Research. 2007;13(21):6359-6368. http://doi.org/10.1158/1078-0432.ccr-07-0660   DOI
25 Stoehlmacher J, Park DJ, Zhang W, Groshen S, Tsao-Wei DD, Yu MC, et al. Association between glutathione S-transferase P1, T1, and M1 genetic polymorphism and survival of patients with metastatic colorectal cancer. Journal of the National Cancer Institute. 2002;94(12):936-942.   DOI
26 Kumamoto K, Ishibashi K, Okada N, Tajima Y, Kuwabara K, Kumagai Y, et al. Polymorphisms of GSTP1, ERCC2 and TS-3'UTR are associated with the clinical outcome of mFOLFOX6 in colorectal cancer patients. Oncology Letters. 2013;6(3):648-654. http://doi.org/10.3892/ol.2013.1467   DOI
27 Zarate R, Rodriguez J, Bandres E, Patino-Garcia A, Ponz-Sarvise M, Viudez A, et al. Oxaliplatin, irinotecan and capecitabine as first-line therapy in metastatic colorectal cancer (mCRC): A dose-finding study and pharmacogenomic analysis. British Journal of Cancer. 2010;102(6):987-994. http://doi.org/10.1038/sj.bjc.6605595   DOI
28 Ruzzo A, Graziano F, Loupakis F, Rulli E, Canestrari E, Santini D, et al. Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy. Journal of Clinical Oncology. 2007; 25(10):1247-1254. http://doi.org/10.1200/jco.2006.08.1844   DOI
29 Chen YC, Tzeng CH, Chen PM, Lin JK, Lin TC, Chen WS, et al. Influence of GSTP1 I105V polymorphism on cumulative neuropathy and outcome of FOLFOX-4 treatment in Asian patients with colorectal carcinoma. Cancer Science. 2010;101(2):530-535. http://doi.org/10.1111/j.1349-7006.2009.01418.x   DOI
30 Oguri T, Mitsuma A, Inada-Inoue M, Morita S, Shibata T, Shimokata T, et al. Genetic polymorphisms associated with oxaliplatin-induced peripheral neurotoxicity in Japanese patients with colorectal cancer. International Journal of Clinical Pharmacology and Therapeutics. 2013;51(6):475-481. http://doi.org/10.5414/CP201851   DOI
31 Basso M, Modoni A, Spada D, Cassano A, Schinzari G, Lo Monaco M, et al. Polymorphism of CAG motif of SK3 gene is associated with acute oxaliplatin neurotoxicity. Cancer Chemotherapy and Pharmacology. 2011;67(5):1179-1187. http://doi.org/10.1007/s00280-010-1466-y   DOI
32 Inada M, Sato M, Morita S, Kitagawa K, Kawada K, Mitsuma A, et al. Associations between oxaliplatin-induced peripheral neuropathy and polymorphisms of the ERCC1 and GSTP1 genes. International Journal of Clinical Pharmacology and Therapheutics. 2010;48(11):729-734.   DOI
33 Kanai M, Kawaguchi T, Kotaka M, Shinozaki K, Touyama T, Manaka D, et al. Large-scale prospective pharmacogenomics study of oxaliplatin-induced neuropathy in colon cancer patients enrolled in the JFMC41-1001-C2 (JOIN Trial). Annals of Oncology. 2016;27(6):1143-1148. http://doi.org/10.1093/annonc/mdw074   DOI
34 Lai JI, Tzeng CH, Chen PM, Lin JK, Lin TC, Chen WS, et al. Very low prevalence of XPD K751Q polymorphism and its association with XPD expression and outcomes of FOLFOX-4 treatment in Asian patients with colorectal carcinoma. Cancer Science. 2009;100(7):1261-1266. http://doi.org/10.1111/j.1349-7006.2009.01186.x   DOI
35 Cecchin E, D'Andrea M, Lonardi S, Zanusso C, Pella N, Errante D, et al. A prospective validation pharmacogenomic study in the adjuvant setting of colorectal cancer patients treated with the 5-fluorouracil/leucovorin/oxaliplatin (FOLFOX4) regimen. The Pharmacogenomics Journal. 2013;13(5):403-409. http://doi.org/10.1038/tpj.2012.31   DOI
36 Custodio A, Moreno-Rubio J, Aparicio J, Gallego-Plazas J, Yaya R, Maurel J, et al. Pharmacogenetic predictors of severe peripheral neuropathy in colon cancer patients treated with oxaliplatin-based adjuvant chemotherapy: A GEMCAD group study. Annals of Oncology. 2014;25(2):398-403. http://doi.org/10.1093/annonc/mdt546   DOI
37 Argyriou AA, Polychronopoulos P, Iconomou G, Koutras A, Makatsoris T, Gerolymos MK, et al. Incidence and characteristics of peripheral neuropathy during oxaliplatin-based chemotherapy for metastatic colon cancer. Acta Oncologica. 2007;46(8):1131-1137. http://doi.org/10.1080/02841860701355055   DOI
38 Sereno M, Gutierrez-Gutierrez G, Rubio JM, Apellaniz-Ruiz M, Sanchez-Barroso L, Casado E, et al. Genetic polymorphisms of SCN9A are associated with oxaliplatin-induced neuropathy. BMC Cancer. 2017;17(1):63. http://doi.org/10.1186/s12885-016-3031-5   DOI
39 Cavaletti G, Alberti P, Marmiroli P. Chemotherapy-induced peripheral neurotoxicity in the era of pharmacogenomics. The Lancet Oncology. 2011;12(12):1151-1161. http://doi.org/10.1016/s1470-2045(11)70131-0   DOI
40 Argyriou AA, Cavaletti G, Antonacopoulou A, Genazzani AA, Briani C, Bruna J, et al. Voltage-gated sodium channel polymorphisms play a pivotal role in the development of oxaliplatin-induced peripheral neurotoxicity: Results from a prospective multicenter study. Cancer. 2013;119(19):3570-3577. http://doi.org/10.1002/cncr.28234   DOI
41 Tofthagen CS, McMillan SC, Kip KE. Development and psychometric evaluation of the chemotherapy-induced peripheral neuropathy assessment tool. Cancer Nursing. 2011;34(4):E10-20. http://doi.org/10.1097/NCC.0b013e31820251de   DOI
42 Argyriou AA, Polychronopoulos P, Iconomou G, Chroni E, Kalofonos HP. A review on oxaliplatin-induced peripheral nerve damage. Cancer Treatment Reviews. 2008;34(4):368-377. http://doi.org/10.1016/j.ctrv.2008.01.003   DOI
43 Chaudhary R, Singh B, Kumar M, Gakhar SK, Saini AK, Parmar VS, et al. Role of single nucleotide polymorphisms in pharmacogenomics and their association with human diseases. Drug Metabolism Reviews. 2015;47(3):281-290. http://doi.org/10.3109/03602532.2015.1047027   DOI